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Background-—Longer QRS duration (QRSd) improves, but increased left ventricular (LV) end-diastolic volume (LVEDV) reduces,
efﬁcacy of cardiac resynchronization therapy (CRT). QRSd/LVEDV ratios differ between sexes. We hypothesized that in the
EchoCRT (Echocardiography Guided Cardiac Resynchronization Therapy) trial enrolling patients with heart failure with QRSd
<130 ms, those with larger LVEDV would deteriorate but those with the highest QRSd/LVEDV would improve with CRT.
Methods and Results-—Primary outcome in patients (n=787, 72% men, 93% New York Heart Association class III, QRSd <130 ms,
LV ejection fraction ≤35%, LV dilation and dyssynchrony) randomized to CRT-ON or CRT-OFF and followed up for 19 months was
compared according to LVEDV (height indexed) or QRSd/LVEDV ratio, in multivariable analysis. Structural remodeling was
assessed echocardiographically 6 months after implantation. Patients with baseline LVEDV higher than or equal to median
worsened with CRT (death/heart failure hospitalization: CRT-ON versus CRT-OFF, 35.2% versus 24.5% [hazard ratio, 1.64; 95%
conﬁdence interval, 1.11–2.42; P=0.012]), but those with LVEDV lower than median remained unaffected. Patients with the highest
QRSd/LVEDV ratio improved with CRT (death/heart failure hospitalization in top quartile: 20.9% in CRT-ON [n=91] versus 28.3% in
CRT-OFF [n=106] [hazard ratio, 0.64; 95% conﬁdence interval, 0.34–1.24; P=0.188], versus the remaining quartiles: 31.7% in CRT-
ON [n=300] versus 24.8% in CRT-OFF [n=290] [hazard ratio, 1.47; 95% conﬁdence interval, 1.07–2.02; P=0.016], test for
interaction P=0.046). QRSd and dyssynchrony were similar between groups. The 3-way test for interaction indicated no sex-
speciﬁc effects. However, numerically, men with LVEDV higher than or equal to median accounted for worse outcomes of CRT-ON.
Women, with the highest QRSd/LVEDV ratio exhibited signiﬁcant reverse remodeling.
Conclusion-—CRT has opposite effects among patients with heart failure with QRSd <130 ms according to LV size: worsening
outcomes in patients with larger LV, but inducing beneﬁcial effects in those with smaller LV.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov/. Unique identiﬁer: NCT00683696. ( J Am Heart Assoc. 2018;7:
e009592. DOI: 10.1161/JAHA.118.009592.)
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A ssessment of QRS duration (QRSd) is a key selectioncriterion for cardiac resynchronization therapy (CRT),
recognizing that there is a spectrum of responses. Indications
reﬂect the greatest probability for successful therapy with
QRSd >150 ms, less (or no) effect for QRSd <150 ms, and
futility (or possible harm) with QRSd <130 ms.1 However,
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there is increasing recognition that QRSd may be prolonged
not only by reduced myocardial conduction velocity (His-
Purkinje lesions) but also by increased left ventricular (LV)
dimension acting to extend the “travel distance” of the
propagating wavefront.2 The distinction is important because
the former is the target for CRT, but the latter (itself
inﬂuenced by heart failure [HF] remodeling, sex, and body
size/height3,4) limits CRT response.5 Hence, any given QRSd
reﬂects the sum effect of factors with opposite implications
for CRT success, and this balance may differ among
individuals with identical QRSd values. The ratio of QRSd/
LV size may better index CRT substrate. When applied, this
was superior to the unadjusted QRSd in predicting successful
CRT measured by short-term hemodynamic effects or long-
term remodeling among patients with left bundle branch block
(LBBB).3,6 Patients with a high index score (relatively large
QRSd and small LV size) had higher probability of CRT
response compared with those with a low index score (smaller
QRS and large LV size) who could worsen with treatment.
Interestingly, this calculation explained CRT inefﬁcacy in some
patients with LBBB and QRSd >150 ms (ie, meeting class I
CRT indications) and conversely why others (principally
women) with narrower QRSd (<150 ms) were successfully
treated by CRT. These observations raise the intriguing notion
that some patients with QRSd <130 ms, together with lower
LV dimensions, may also beneﬁt from CRT.
We tested this hypothesis post hoc in the EchoCRT
(Echocardiography Guided Cardiac Resynchronization Ther-
apy) trial, which evaluated CRT effect among patients with
QRSd <130 ms and LV dilatation,7 hypothesizing that patients
with larger LV end-diastolic volume (LVEDV) would deteriorate
but those with the highest QRSd/LVEDV would improve with
CRT. In addition, because among conventionally selected
patients undergoing CRT (LBBB and LV ejection fraction
[LVEF] <35%), men have greater LV dilation,3,6 and numeri-
cally a higher all-cause mortality was reported in male
patients randomized to CRT-ON in the EchoCRT trial,8 we
assessed interactions of sex with LV size and CRT effect.
Methods
Study Design and Conduct
The study was approved by an institutional review board at
each participating site, and participants gave written informed
consent. The data, analytic methods, and study materials will
not be made available to other researchers for purposes of
reproducing the results or replicating the procedure. The
study protocol and main outcome results of the EchoCRT trial
were reported previously.7 In brief, patients with New York
Heart Association class III or IV HF with LVEF of ≤35%,
optimized medical therapy with QRSd <130 ms and LV end-
diastolic diameter ≥55 mm, and echocardiographic evidence
of LV dyssynchrony were randomized 1:1 to CRT-OFF (control)
or CRT-ON. Device-implanting physicians and physicians
involved in the follow-up were aware of the study group
assignment, whereas patients, HF physicians, and study
personnel completing the follow-up assessments were not.
The trial was terminated early after interim analysis because
of futility in reaching the primary end point and an observed
overall increase in mortality in the CRT-ON group.
The current analysis was directed towards assessment of
the impact of LV size and QRSd/LV size ratio on the effect of
CRT in the EchoCRT trial cohort. QRSd was determined from a
standard 12-lead ECG recorded at 25 mm/s before implan-
tation, submitted to the ECG Core Laboratory (University of
Glasgow, Glasgow, UK), and echocardiographic data from the
Echo Core Laboratory (University of Pittsburgh Medical
Center, Pittsburgh, PA). All readers were blinded to the
treatment group assignment and any clinical data. Correla-
tions between QRSd, LV size, and height were assessed. LV
size was derived from preimplantation biplane LVEDV and
indexed to height to account for inﬂuence of body size
(indexed volumes [mL/m] are reported throughout this
article). Then, enrolled patients were dichotomized by median
LVEDV value (LVEDVMedian). Because LV size generally is
larger in male CRT recipients,3,6 and men were the driver for
worse outcomes with CRT in the whole EchoCRT trial cohort,8
we compared CRT effect according to LV size in each sex. We
then assessed the quotient QRSd/LVEDV to test the hypoth-
esis that patients with larger QRSd/LVEDV ratios beneﬁted
from CRT. Because LV enlargement was a criterion for
inclusion (thus restricting the available patient population with
Clinical Perspective
What Is New?
• Although the overall results of the EchoCRT (Echocardiog-
raphy Guided Cardiac Resynchronization Therapy) trial
indicated futility or even harm of using cardiac resynchro-
nization therapy in patients with heart failure with QRS
duration <130 ms, we discovered that the risk was
concentrated among those with larger left ventricular
dimensions; conversely patients with longer QRS duration
and smaller left ventricular size appeared to beneﬁt from
cardiac resynchronization therapy.
What Are the Clinical Implications?
• The assessment of nonelectrical modulators (eg, left
ventricular size, sex, and stature) in patients with heart
failure may reveal a group with “narrow” QRS duration and
smaller ventricles who beneﬁt from cardiac resynchroniza-
tion therapy.
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lower LVEDV), we compared CRT effects in patients stratiﬁed
in the top quartile (ie, quartile 4 [Q4]; QRSd/LVEDVQ4) versus
the remainder (ie, quartile 1–quartile 3 [Q1–Q3]; QRSd/
LVEDVQ1–Q3). This permitted identiﬁcation of the subgroup of
patients with the least contribution of LV enlargement to QRS
prolongation and evaluation of their outcome according to the
randomized treatment.
Outcomes were assessed by the prespeciﬁed primary
efﬁcacy outcome (combination of death from any cause and
ﬁrst hospitalization for worsening HF) and secondary out-
comes (ie, all hospitalizations for worsening HF throughout
the study, all-cause mortality, and cardiovascular mortality).7
In addition, we measured changes in echocardiographic
structural remodeling from baseline to 6 months after
implantation. The combination of LVEF increase of ≥5% and
LV end-systolic volume decrease of ≥10% was used as a
measure of positive CRT effect.9 Results were compared
between sexes.
Statistical Analysis
The study results were analyzed at the independent Statistical
Centre at the Robertson Centre for Biostatistics, University of
Glasgow. (One of us [N.V.] had full access to all the data in the
study and takes responsibility for its integrity and the data
analysis.) Baseline characteristics were reported as means
and SDs for continuous variables and counts and percentages
for categorical variables, and treatment group comparisons
were based on 2-sample t test (or Mann-Whitney test) and v2
(or Fisher’s exact) tests, as appropriate. For primary and
secondary outcome analyses, interactions between treatment
effects (CRT-ON and CRT-OFF) and selected groups (ie,
dichotomized by LVEDVMedian and QRSd/LVEDVQ4 versus
QRSd/LVEDVQ1–Q3) were tested for in Cox proportional
hazard models. These models included hazard ratios (HRs)
with 95% conﬁdence intervals (CIs) that included treatment
(CRT-ON and CRT-OFF) adjustments for the following baseline
characteristics: sex, country, walking distance, quality-of-life
score, sitting systolic blood pressure, ischemic cardiomyopa-
thy, history of myocardial infarction, history of coronary artery
bypass grafting, and diuretic use. (The same characteristics,
except sex, were used in independent male/female compar-
isons, followed by 3-way test for interaction.) Time-to-event
curves were estimated using the Kaplan-Meier method with
the log-rank test. Follow-up was censored at study closure,
date of death, LV assist device implantation, heart transplant,
withdrawal from the study, or unavailability for follow-up,
whichever came ﬁrst.
For structural remodeling analyses, the proportions of
patients with events were compared among groups using a v2
test. Tests for interaction were analyzed using a logistic
regression model with CRT randomized treatment and
baseline LVEDV grouping included as explanatory variables
along with an interaction term. Correlations were reported
using the Pearson correlation coefﬁcient.
All tests were 2 sided, with P<0.05 considered to be
signiﬁcant.
Results
A total of 809 patients were randomized in the EchoCRT trial
(405 to CRT-OFF group [control] and 404 to CRT-ON group).
The mean follow-up was 19.4 months for all patients and
19.8 months for surviving patients. The study visit compliance
rate among patients was 95.5%. Overall patient characteris-
tics in our substudy (n=796) did not differ from the whole trial
cohort7 (eg, age, 5813 years; 72% men; New York Heart
Association class III, 94%; LVEF, 276%; LV end-diastolic
diameter, 668 mm; LVEDV [uncorrected], 19059 mL;
ischemic cardiomyopathy, 53%; hypertension, 66%; diabetes
mellitus, 40%; chronic lung disease, 19%; chronic kidney
disease, 13%; QRSd [Core Laboratory], 10613 ms). Corre-
lation (coefﬁcient r) of QRSd with LVEDV was 0.32
(P<0.001); LVEDV/height, 0.32 (P<0.001); LVEF, 0.09
(P<0.01); height, 0.04 (P=0.32); and body mass index, 0.04
(P=0.23). Among patients with available 6-month follow-up
echocardiograms (CRT-ON versus CRT-OFF, n=313 versus
n=312), there was a larger proportion demonstrating
improvement in LV function with CRT (36.4% versus 28.2%;
P=0.028), but most patients in each group showed no
change or deterioration.
LV Size and Outcome
This study group (796 patients with available echocardio-
graphic studies; CRT-ON, n=398; and CRT-OFF, n=398) was
dichotomized by LVEDVMedian/height (105.9 mL/m;
interquartile range [IQR], 87.1–127.4 mL/m). Group
characteristics are contrasted in Table 1. LV end-diastolic
diameter was 11.6% and LVEDV (uncorrected) was 59.4%
greater in LVEDV≥Median versus LVEDV<Median. Patients with
LVEDV≥Median were younger, were more frequently men
(80%) with wider QRSd, had larger body mass index, had
less diabetes mellitus, had lower LVEF, and less frequently
had underlying ischemic cardiomyopathy. Groups did not
differ for dyssynchrony (Table 1), lead position (Table 2), or %
CRT pacing (97.74.85% versus 97.44.69%; P=0.51).
CRT did not affect any of the measured outcomes in
patients with LVEDV<Median (Table 3). In contrast, among
patients with LVEDV≥Median, the primary outcome was wors-
ened signiﬁcantly by CRT (Figure 1A) and there were more
deaths, both overall (P=0.002) and attributable to cardiovas-
cular causes (P=0.001; signiﬁcant test for interaction
P=0.036) (Table 3). When compared, LV structural
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Table 1. Characteristics of Patients at Baseline by LVEDV/Height Grouping
Variable
Less Than
Median, n
Less Than Median,
statistic
Greater Than or
Equal to Median, n
Greater Than or Equal to
Median, statistic P Value
Age, y 398 60.9 (11/43) 398 55.1 (13.31) <0.001
Men 398 258 (64.82) 398 316 (79.40) <0.001
QRS width (site) ms 398 102.9 (12.37) 398 107.6 (12.83) <0.001
QRS width (core) ms 394 102.7 (12.00) 393 108.9 (12.36) <0.001
Walking distance, m 390 310.8 (119.66) 390 339.7 (118.41) <0.001
Quality-of-life score 395 51.1 (24.27) 398 51.4 (24.47) 0.830
NYHA classification
I 398 1 (0.25) 398 4 (1.01) *
II 398 4 (1.01) 398 15 (3.77)
III 398 379 (95.23) 398 368 (92.46)
IV 398 14 (3.52) 398 11 (2.76)
BNP, pg/mL 201 240.0 (92.00–586.00) 189 281.0 (112.00–515.00) 0.284
NT-proBNP, pg/mL 184 915.0 (409.50–2331.0) 191 1250.0 (587.00–2373.0) 0.128
Sitting SBP, mm Hg 398 118.8 (18.80) 398 118.6 (20.01) 0.894
Sitting DBP, mm Hg 398 72.0 (11.48) 398 73.4 (12.42) 0.097
BMI, kg/m2 397 29.2 (6.52) 398 32.5 (15.81) <0.001
Height, cm 397 170.4 (10.1) 398 172.6 (13.9) 0.012
Ischemic cardiomyopathy 397 236 (59.45) 398 191 (47.99) 0.001
Myocardial infarction >3 mo ago 398 170 (42.71) 398 148 (37.19) 0.111
Percutaneous coronary intervention >3 mo ago 398 157 (39.45) 398 130 (32.66) 0.046
CABG >3 mo ago 398 86 (21.61) 398 63 (15.83) 0.037
Hypertension 391 271 (69.31) 398 256 (64.32) 0.137
Prior ischemic stroke or TIA 396 51 (12.88) 394 44 (11.17) 0.460
Diabetes mellitus 396 173 (43.69) 397 142 (35.77) 0.023
Chronic lung disease 395 72 (18.23) 394 74 (18.78) 0.841
Chronic kidney disease 394 56 (14.21) 396 49 (12.37) 0.446
LVEF biplane, % 398 28.7 (4.93) 398 25.2 (5.55) <0.001
LV end-diastolic diameter, mm 398 62.7 (5.48) 398 70.0 (7.42) <0.001
LVEDV, mL 145.7 (26.2) 232.2 (49.9) <0.001
Qualified by TDI and/or radial strain dyssynchrony
TDI only 397 111 (27.96) 398 85 (21.36) 0.061
Radial strain only 397 81 (20.40) 398 100 (25.13)
TDI and radial strain 397 205 (51.64) 398 213 (53.52)
Medication
ACE inhibitor or ARB 398 374 (93.97) 398 382 (95.98) 0.194
Aldosterone antagonist 398 220 (55.28) 398 257 (64.57) 0.007
b Blocker 398 385 (96.73) 398 384 (96.48) 1.000
Diuretic agent 398 336 (84.42) 398 351 (88.19) 0.122
Categorical variable number (percentage) values are reported. Continuous variable mean (SD) values are reported, except for BNP and NT-proBNP, for which median (interquartile range)
values are presented. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, brain natriuretic peptide; CABG, coronary artery
bypass grafting; DBP, diastolic blood pressure; LV, left ventricular; LVEDV, LV end-diastolic volume; LVEF, LV fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New
York Heart Association; SBP, systolic blood pressure; TDI, tissue Doppler imaging; and TIA, transient ischemic attack.
*P value not reported because of small numbers.
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improvement was better with CRT-ON in LVEDV<Median than
with CRT-OFF (38.8% [n=59] versus 27% [n=44]; P=0.025),
but unchanged in LVEDV≥Median (but interaction between the
CRT treatment and the LVEDV grouping was nonsigniﬁcant:
P=0.34).
Sexes were tested separately. Men had larger LVEDV than
women (median, 109.6 [IQR, 91.2–130.6] versus 96.2 [80.8–
116.3] mL/m; P<0.001). CRT in men with LVEDV<Median(Men)
had no effect. In contrast, outcomes were signiﬁcantly
worsened by CRT in LVEDV≥Median(Men) (Table 4; Figure 1B).
The primary outcome was observed more frequently in this
group (Figure 1B). Cardiovascular death and number of
patients with HF hospitalizations increased signiﬁcantly
(Table 4). Thus, during the trial, 21 of 150 patients with
LVEDV≥Median(Men) (14%) in the CRT-ON group experienced
cardiovascular death, compared with 4 of 137 (2.9%) in the
CRT-OFF group (HR, 7.85; 95% CI, 2.17–28.32; P=0.002;
signiﬁcant test for interaction with LVEDV<Median(Men)
P=0.034). The number of patients with HF hospitalizations
increased with CRT: 46 of 150 patients with LVEDV≥Median(Men)
(30.7%) in CRT-ON group versus 25 of 137 (18.25%) in the
control group (HR, 1.99; 95% CI, 1.17–3.38; P=0.011; test for
interaction with LVEDV<Median(Men) P=0.039). No signiﬁcant LV
structural changes occurred at 6 months after implantation
among men (n=450) with CRT-ON (n=231) versus CRT-OFF
(n=219) in either LVEDV≥Median(Men) or LVEDV<Median(Men).
In women, CRT did not worsen outcomes in LVEDV≥
Median(Women) compared with LVEDV<Median(Women), but analysis
is limited by the relatively few patients in each group and paucity
of events (Table 4; Figure 1C). Among women (n=175), CRT
resulted in no change in LVEDV≥Median(Women), but positive
structural remodeling occurred in LVEDV<Median(Women) (46.5%
versus 25% in CRT-OFF; P=0.03 [although test for interaction
was nonsigniﬁcant {P=0.25}]).
A 3-way test of interaction to test whether sex inﬂuenced
effects of LVEDV on the relationship between CRT and
outcome found no difference between men and women for
any of the end points.
Table 3. End Point Results by LVEDV Grouping, All Subjects
End Point Subgroup CRT-OFF
CRT-OFF, No.
(%) With Event CRT-ON
CRT-ON, No.
(%) With Event
Fully Adjusted Hazard Ratio
(95% Conﬁdence Interval),
P Value*
P Value for Interaction
Between Randomized
Treatment and
Groupings
Death or HF
hospitalization
Less than median 203 54 (26.60) 195 44 (22.56) 0.95 (0.62–1.44), 0.793 0.056
Greater than or
equal to median
196 48 (24.49) 202 71 (35.15) 1.64 (1.11–2.42), 0.012
Death Less than median 203 17 (8.37) 195 18 (9.23) 1.19 (0.58–2.44), 0.631 0.054
Greater than or
equal to median
196 9 (4.59) 202 26 (12.87) 3.71 (1.60–8.61), 0.002
HF hospitalization Less than median 203 44 (21.67) 195 36 (18.46) 0.96 (0.60–1.53), 0.857 0.149
Greater than or
equal to median
196 46 (23.47) 202 62 (30.69) 1.52 (1.01–2.27), 0.042
CVD death Less than median 203 11 (5.42) 195 13 (6.67) 1.37 (0.58–3.22), 0.477 0.036
Greater than or
equal to median
196 6 (3.06) 202 23 (11.39) 5.26 (1.93–14.30), 0.001
CRT indicates cardiac resynchronization therapy; CVD, cardiovascular disease; HF, heart failure; and LVEDV, left ventricular end-diastolic volume.
*Hazard ratio (95% conﬁdence interval) adjusted for country, sex, walking distance, quality of life, sitting diastolic blood pressure, ischemic cardiomyopathy, history of myocardial
infarction, history of coronary artery bypass grafting, and diuretic use; P value from Wald test.
Table 2. LV Lead Location, by Study Grouping
Location
Less Than
Median (n=332)
Greater Than or
Equal to Median (n=316)
Study grouping: LVEDV
Basal 59 (17.8) 64 (20.3)
Mid 214 (64.5) 207 (65.5)
Apical 59 (17.8) 45 (14.2)
P=0.40
Q1–Q3 (n=481) Q4 (n=160)
Study grouping: QRS/LVEDV
Basal 93 (19.3) 30 (18.8)
Mid 315 (65.5) 101 (63.1)
Apical 73 (15.2) 29 (18.1)
P=0.68
Data are given as number (percentage). LV indicates left ventricular; LVEDV, LV end-
diastolic volume; and Q, quartile.
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QRSd/LVEDV Ratio and Outcome
The QRS and LV size analysis population included 787
patients with core laboratory electrocardiographic analyses
(396 in CRT-OFF and 391 in CRT-ON). Among 621 patients
with available echocardiographic data (CRT-ON versus CRT-
OFF, n=311 versus n=310), there was a larger proportion
demonstrating improvement in LV function with CRT at
6 months after CRT (36.3% versus 27.7%; P=0.022).
QRSd/LVEDV ratio in the overall population was a
median of 0.99 ms/mL per m (IQR, 0.83–1.19 ms/mL per
Figure 1. Cardiac resynchronization therapy (CRT) effect by left ventricular (LV) size: primary
outcomes. Primary outcomes (death from any cause or hospitalization for worsening heart failure) are
reported in patient groups dichotomized by median values of LV end-diastolic volume (LVEDV). A,
Overall. Left panel: Among patients with LVEDV lower than median (LVEDV<Median), CRT had no
signiﬁcant effect. Right panel: In contrast, among those patients with LVEDV is higher than or equal to
median(LVEDV≥Median),theprimaryoutcomeoccurredin71of202patients(35.2%)intheCRT-ONgroup
vs 48 of 196patients (24.5%) in the control group (hazard ratiowithCRT, 1.64; 95% conﬁdence interval
[CI], 1.11–2.42;P=0.012). B,Men. Left panel: In LVEDV<Median(Men), CRT had no signiﬁcant effect. Right
panel: In LVEDV≥Median(Men), the primary outcome occurred in 54 of 150 patients (36%) in the CRT-ON
groupvs27of137patients (19.7%) inthecontrolgroup (hazard ratiowithCRT,2.14;95%CI,1.30–3.55;
P=0.003; signiﬁcant test for interaction with LVEDV<Median[Men] P=0.018). C, Women. CRT had no
signiﬁcant effect in women, with LVEDV<Median(Women) (left panel) or LVEDV≥Median(Women) (right panel).
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m). QRSd/LVEDVQ4 patients, when compared with QRSd/
LVEDVQ1–Q3 patients, were older and less tall, with a higher
proportion of women, had higher LVEF, and more frequently
had underlying ischemic cardiomyopathy, lower body mass
index, and more diabetes mellitus (Table 5). LV end-
diastolic diameter was 11.6%, and LVEDV (uncorrected)
was 60.5% greater in QRSd/LVEDVQ1–Q3 patients compared
with QRSd/LVEDVQ4 patients. There was no difference
between groups for dyssynchrony, QRSd, LV lead position
(Table 2), or %CRT pacing (97.54.88% versus 97.64.53%;
P=0.87).
After a mean follow-up of 19.4 months, CRT elicited
opposite effects in study groups (Table 6, Figure 2). In
multivariable analysis, CRT-ON increased the proportion of
patients reaching the primary end point in QRSd/LVEDVQ1–
Q3 (31.7% in CRT-ON [n=300] versus 24.8% in CRT-OFF
[n=290]; HR, 1.47; 95% CI, 1.07–2.02; P=0.016), but
decreased it in QRSd/LVEDVQ4 (death/HF hospitalization,
20.9% in CRT-ON [n=91] versus 28.3% in CRT-OFF [n=106];
HR, 0.64; 95% CI, 0.34–1.24; borderline signiﬁcant test for
interaction P=0.046). Stronger differences were observed for
all-cause mortality (test for interaction P=0.038). Reverse
structural remodeling was increased in QRSd/LVEDVQ4
(Figure 3A). Hence, patients in QRSd/LVEDVQ4 gained ben-
eﬁt from CRT.
Effects in each sex were evaluated separately. QRSd/
LVEDV ratio was greater in women (median, 1.1 [IQR, 0.9–1.3]
ms/mL) versus men (median, 1.0 [IQR, 0.8–1.2] ms/mL;
P<0.001). Among men, primary or secondary outcomes were
unaffected by CRT in QRSd/LVEDVQ4 Men but signiﬁcantly
worsened in QRSd/LVEDVQ1–Q3 Men (Table 7). In women,
outcomes were unaffected by CRT in QRSd/LVEDVQ1–Q3
Women or QRSd/LVEDVQ4 Women (Table 7). A 3-way test of
interaction to test whether sex inﬂuenced effects of QRSd/
LVEDV on the relationship between CRT and outcome found
no difference between men and women for any of the end
points. (However, the few female patients in QRSd/LVEDVQ4
[CRT-ON=22; CRT-OFF=24] and paucity of events occurring
during the time interval assessed may underpower this
comparison.) Echocardiographic data were available in 175
Table 4. End Point Results by LVEDV Grouping Separated by Sex
End Point Subgroup CRT-OFF
CRT-OFF, No.
(%) With Event CRT-ON
CRT-ON, No.
(%) With Event
Fully Adjusted Hazard Ratio
(95% Conﬁdence Interval),
P Value*
P Value for
Interaction
Between
Randomized
Treatment and
Groupings
Men (n=574)
Death or HF
hospitalization
Less than median 148 41 (27.70) 139 31 (22.30) 0.95 (0.57–1.58), 0.838 0.018
Greater than or equal to median 137 27 (19.71) 150 54 (36.00) 2.14 (1.30–3.55), 0.003
Death Less than median 148 14 (9.46) 139 15 (10.79) 1.32 (0.59–2.96), 0.498 0.084
Greater than or equal to median 137 7 (5.11) 150 24 (16.00) 4.16 (1.57–11.04), 0.004
HF hospitalization Less than median 148 32 (21.62) 139 23 (16.55) 0.90 (0.50–1.62), 0.728 0.039
Greater than or equal to median 137 25 (18.25) 150 46 (30.67) 1.99 (1.17–3.38), 0.011
CVD death Less than median 148 9 (6.08) 139 11 (7.91) 1.35 (0.51–3.61), 0.547 0.034
Greater than or equal to median 137 4 (2.92) 150 21 (14.00) 7.85 (2.17–28.32), 0.002
Women (n=222)
Death or HF
hospitalization
Less than median 55 13 (23.64) 56 12 (21.43) 0.61 (0.24–1.54), 0.295 0.530
Greater than or equal to median 59 21 (35.59) 52 18 (34.62) 1.13 (0.53–2.44), 0.753
Death Less than median 55 3 (5.45) 56 3 (5.36) 0.70 (0.11–4.27), 0.699 0.841
Greater than or equal to median 59 2 (3.39) 52 2 (3.85) 0.63 (0.03–12.19), 0.758
HF hospitalization Less than median 55 12 (21.82) 56 12 (21.43) 0.68 (0.27–1.76), 0.430 0.730
Greater than or equal to median 59 21 (35.59) 52 17 (32.69) 1.08 (0.50–2.37), 0.838
CVD death Less than median 55 2 (3.64) 56 2 (3.57) 0.44 (0.04–5.48), 0.527 0.640
Greater than or equal to median 59 2 (3.39) 52 2 (3.85) 0.63 (0.03–12.19), 0.758
Three-way test of interaction of sex with effects of LVEDV/height on CRT effect for outcomes: death/HF hospitalization, P=0.23; death, P=0.52; HF hospitalization, P=0.19; and CVD death,
P=0.47. CRT indicates cardiac resynchronization therapy; CVD, cardiovascular disease; HF, heart failure; and LVEDV, left ventricular end-diastolic volume.
*Hazard ratio (95% conﬁdence interval) adjusted for country, walking distance, quality of life, sitting diastolic blood pressure, ischemic cardiomyopathy, history of myocardial infarction,
history of coronary artery bypass grafting, and diuretic use; P value from Wald test.
DOI: 10.1161/JAHA.118.009592 Journal of the American Heart Association 7
CRT in Patients With Heart Failure With Narrow QRS Varma et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on August 14, 2019
Table 5. Characteristics of Patients at Baseline by QRS/LVEDV Grouping, All Subjects
Variable Q1–Q3, n Q1–Q3, statistic Q4, n Q4, statistic P Value
Age, y 590 56.3 (12.85) 197 63.1 (11.11) <0.001
Men 590 442 (74.92) 197 123 (62.44) <0.001
QRS width (site) ms 590 104.8 (12.81) 197 106.3 (12.85) 0.168
QRS width (core) ms 590 105.5 (12.26) 197 107.0 (13.38) 0.146
Walking distance, m 581 328.5 (119.02) 191 313.7 (120.70) 0.137
Quality-of-life score 588 51.6 (24.73) 196 49.8 (23.24) 0.362
NYHA classification
I 590 4 (0.68) 197 1 (0.51) *
II 590 16 (2.71) 197 2 (1.02)
III 590 552 (93.56) 197 188 (95.43)
IV 590 18 (3.05) 197 6 (3.05)
BNP, pg/mL 292 240.0 (109.00–569.00) 95 226.0 (72.00–540.00) 0.110
NT-proBNP, pg/mL 276 1167.0 (535.50–2328.5) 94 919.0 (443.00–2356.0) 0.720
Sitting SBP, mm Hg 590 118.2 (19.23) 197 120.3 (19.37) 0.193
Sitting DBP, mm Hg 590 72.9 (12.10) 197 72.4 (11.13) 0.578
BMI, kg/m2 590 31.7 (13.57) 196 28.2 (6.28) <0.001
Height cm 590 172.2 (12.78) 196 169.2 (10.35) 0.003
Ischemic cardiomyopathy 589 301 (51.10) 197 121 (61.42) 0.012
Myocardial infarction >3 mo ago 590 231 (39.15) 197 82 (41.62) 0.539
Percutaneous coronary
intervention >3 mo ago
590 210 (35.59) 197 75 (38.07) 0.531
CABG >3 mo ago 590 105 (17.80) 197 42 (21.32) 0.272
Hypertension 587 392 (66.78) 193 129 (66.84) 0.988
Prior ischemic stroke or TIA 585 68 (11.62) 196 24 (12.24) 0.815
Diabetes mellitus 588 229 (38.95) 196 82 (41.84) 0.474
Chronic lung disease 585 111 (18.97) 195 35 (17.95) 0.750
Chronic kidney disease 587 75 (12.78) 194 28 (14.43) 0.554
LVEF biplane, % 590 26.1 (5.56) 197 29.8 (4.31) <0.001
LV end-diastolic diameter, mm 590 68.0 (7.32) 197 61.4 (5.59) <0.001
LVEDV, mL 208.5 (53.8) 129.9 (23.7) <0.001
Qualified by TDI and/or radial strain dyssynchrony
TDI only 590 138 (23.39) 196 56 (28.57) 0.188
Radial strain only 590 142 (24.07) 196 37 (18.88)
TDI and radial strain 590 310 (52.54) 196 103 (52.55)
Medication
ACE inhibitor or ARB 590 563 (95.42) 197 184 (93.40) 0.263
Aldosterone antagonist 590 364 (61.69) 197 108 (54.82) 0.088
b Blocker 590 569 (96.44) 197 192 (97.46) 0.646
Diuretic agent 590 519 (87.97) 197 162 (82.23) 0.041
Categorical variable number (percentage) values are reported. Continuous variable mean (SD) values are reported, except for BNP and NT-proBNP, for which median (interquartile range)
values are presented. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, brain natriuretic peptide; CABG, coronary artery
bypass grafting; DBP, diastolic blood pressure; LV, left ventricular; LVEDV, LV end-diastolic volume; LVEF, LF ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA,
New York Heart Association; Q, quartile; SBP, systolic blood pressure; TDI, tissue Doppler imaging; and TIA, transient ischemic attack.
*P value not reported because of small numbers.
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women (CRT-ON versus CRT-OFF, 82 versus 93) and 446 men
(CRT-ON versus CRT-OFF, 229 versus 217). No signiﬁcant
changes were observed in men (Figure 3B). However, CRT
elicited signiﬁcant reverse remodeling in QRSd/LVEDVQ4
Women (Figure 3C).
Discussion
Among patients with HF with QRSd <130 ms in the EchoCRT
trial, those with larger LV dimensions deteriorated with
treatment, but in contrast those with larger QRSd and smaller
LV size appeared to beneﬁt from CRT. Baseline dyssynchrony
did not separate these groups.
The QRSd represents the time taken for the electrical wave
of myocardial depolarization to move from the His-Purkinje
system through the ventricular myocardium. It is prolonged
most obviously by HPS delay (eg, LBBB) but also by increased
LV dimension, which increases “path length.”2 LV size itself
may increase with cardiomyopathy and larger body size.
These correlations have been observed in healthy subjects
and in patients with cardiomyopathy and LBBB.10–14 Among
patients with normal QRSd with normal LV function, Stewart
et al found that each 10 ms increase in QRSd was associated
with a 9.2% increase in LVEDV.13 Moreover, increase in QRSd
was associated with greater height (but not body mass index).
We report similar, although modest, correlations in our
population with HF with “narrow” QRSd (<130 ms). The
correlation of QRSd and LVEDV was 0.32, and the correlation
of LVEDV with patient height was 0.30 (thus, reported LVEDV
values were normalized for height [mL/m]). No sex differ-
ences were observed. However, although a prior study of
patients with normal QRSd (but no cardiomyopathy) found no
signiﬁcant sex difference across QRSd when linked to LVEDV
and height,13 here in patients with narrow QRS and HF, we
discovered a slight (10%) but signiﬁcant sex difference in
QRSd/LVEDV/height. These interactions are important
because any given value of QRSd, the determinant of any
individual’s candidacy for CRT, represents a composite result
of delayed myocardial conduction (ie, the substrate for CRT)
but also increased LV size (mass/volume), which may degrade
CRT beneﬁt.5 The ratio of QRSd/LV size was shown recently
to be a better predictor of CRT effect than QRSd alone in
patients with LBBB, and it differed between sexes and among
individuals.3,6
Herein, we extended these principles to patients with HF
with QRSd <130 ms. First, we tested the impact of LV size,
noting that the EchoCRT trial enrolled patients with LV
dilatation (assessed by LV diameter). LV volume ranged
widely, but QRSd ranged only slightly. We discovered that CRT
effect was neutral in those with LVEDV<Median, but it was
deleterious in patients with LVEDV≥Median (Figure 1). (This
observation is consistent with the negative impact of larger LV
size on the success of CRT applied for standard indications.5)
This may explain our prior result that male patients determined
the worse outcomes of CRT-ON for the entire EchoCRT trial
cohort8: more men were enrolled, and their LV size was larger,
but this was not a sex-speciﬁc effect, according to our results.
Next, we assessed the impact of QRSd/LV size stratiﬁed by
quartiles. The primary outcome was worsened among patients
treated by CRT in those with lower QRSd/LV size, but it was
possibly improved in the highest quartile (QRSd/LVEDVQ4)
(Figure 2) (similar to prior observations in patients with
LBBB3,6). Effects on overall death and on structural remodeling
indexes were consistent, with CRT beneﬁt in QRSd/LVEDVQ4.
Table 6. End Point Results by QRSd/LVEDV Grouping, All Subjects
End Point Subgroup CRT-OFF
CRT-OFF, No.
(%) With Event CRT-ON
CRT-ON, No.
(%) With Event
Fully Adjusted Hazard
Ratio (95% Conﬁdence Interval),
P Value*
P Value for
Interaction Between
Randomized
Treatment and
Groupings
Death or HF
hospitalization
Q1–Q3 290 72 (24.83) 300 95 (31.67) 1.47 (1.07–2.02), 0.016 0.046
Q4 106 30 (28.30) 91 19 (20.88) 0.64 (0.34–1.24), 0.188
Death Q1–Q3 290 16 (5.52) 300 35 (11.67) 2.53 (1.36–4.72), 0.003 0.038
Q4 106 10 (9.43) 91 8 (8.79) 0.74 (0.24–2.31), 0.609
HF hospitalization Q1–Q3 290 66 (22.76) 300 82 (27.33) 1.40 (1.00–1.95), 0.050 0.104
Q4 106 24 (22.64) 91 15 (16.48) 0.63 (0.31–1.28), 0.203
CVD death Q1–Q3 290 11 (3.79) 300 29 (9.67) 3.13 (1.51–6.47), 0.002 0.079
Q4 106 6 (5.66) 91 6 (6.59) 1.00 (0.22–4.59), 1.000
CRT indicates cardiac resynchronization therapy; CVD, cardiovascular disease; HF, heart failure; LVEDV, left ventricular end-diastolic volume; Q, quartile; and QRSd, QRS duration.
*Hazard ratio (95% conﬁdence interval) adjusted for country, sex, walking distance, quality of life, sitting diastolic blood pressure, ischemic cardiomyopathy, history of myocardial
infarction, history of coronary artery bypass grafting, and diuretic use; P value from Wald test.
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Notably, although CRT elicited opposite effects in these 2
groups (ie QRSd/LVEDVQ1–Q3 vs QRSd/LVEDVQ4), QRSd and
echocardiographic dyssynchrony indexes were similar (ie,
these were not differentiators). There was a signiﬁcant sex
difference in QRSd/LVEDV ratio: it was greater in women.
Despite this favorable substrate, no sex difference between
CRT response in QRSd/LVEDVQ1–Q3 and QRSd/LVEDVQ4 was
found in multivariable analysis for the primary and secondary
outcomes. Although there were proportionally more women in
QRSd/LVEDVQ4, they were still a minority (CRT-ON versus
CRT-OFF, 22 versus 24) and experienced few events,
underpowering this comparison. Interestingly, improved struc-
tural remodeling in QRSd/LVEDVQ4 was largely accounted for
by CRT effects in women (Figure 3).
The demonstration that some patients with QRS <130 ms
may derive beneﬁt from CRT may appear counterintuitive,
because CRT aims to reverse delayed LV depolarization,
typically LBBB. However, normal QRSd is 85 to 92 ms, and
the cut point of 120 ms to select “wide” was arbitrarily
deﬁned.11,15–17 Hence, it is conceivable that some patients
with QRSd <130 ms may have signiﬁcant LV conduction delay
that may form the substrate for successful CRT. However,
simple QRSd cut points failed to separate subgroups with
positive response to CRT in the EchoCRT trial, as reported
previously.18 Outcomes of patients with QRSd 120 to 130 ms
did not differ from those with QRSd <120 ms. Elsewhere, it is
well appreciated that accepted LBBB criteria may be seen
with QRSd <130 ms, usually in women with smaller stature,
and CRT may be beneﬁcial, an effect attributed to smaller
heart size.11 Inclusion of height (and presumably its effect on
LV size) in an individual patient meta-analysis of randomized
CRT trials supported CRT beneﬁt for patients of shorter
stature and QRS <130 ms.4 Conversely, a nonresponse rate
of >20% persisted among patients undergoing CRT with class I
indications (LBBB and QRS >150 ms), minimal comorbidities,
and well-sited LV leads, an effect at least partially attributable
to excessive LV dilatation.3 Collectively, these reports may
explain why QRSd alone is an incomplete predictor of CRT
response. Although this inﬂuence of LV size on QRSd is
recognized in electrocardiographic guidelines,2 it has not been
included in the electrocardiographic criteria exercised for CRT
selection.
Our results have signiﬁcant implications. There has been
recurring interest in transferring the well-established beneﬁts
of CRT in patients with HF with a wide QRSd to those with
narrow QRSd (<130 ms), who account for most patients with
HF. Despite anecdotal experience and initial promise from
small studies selecting narrow QRSd patients on the basis of
echocardiographic evidence of dyssynchrony, results from
subsequent randomized trials have been disappointing.19
Indeed, the overall results of the EchoCRT trial pointed to
futility of CRT. The current study shows that inclusion of LV
dimension and height in conjunction with QRSd separated
groups who were harmed versus others who may gain beneﬁt.
Because the trial required LV dilation for enrollment, male
patients (72%) dominated the cohort and determine overall
trial results. Under these conditions, the isolation of a
minority sustaining a positive effect is all the more striking.
Because this group was characterized by smallest LV size, and
the trial excluded patients with LV diastolic diameter
<55 mm, it likely underrepresents the fraction of patients
with HF with QRS <130 ms but high QRSd/LVEDV ratio in the
community.
Figure 2. Cardiac resynchronization therapy (CRT)
effect by the ratio of QRS duration (QRSd)/left ventricular
(LV) size: primary outcomes. Primary end point (death
from any cause or hospitalization for worsening heart
failure) is contrasted for treatment effects in patients
grouped according to quartile (Q) ranges (QRSd/LV end-
diastolic volume [LVEDV]Q1–Q3 vs QRSd/LVEDVQ4). CRT
caused deterioration in QRSd/LVEDVQ1–Q3 but improve-
ment in QRSd/LVEDVQ4 (hazard ratio, 0.64; 95% conﬁ-
dence interval, 0.34–1.24; signiﬁcant test for interaction
P=0.046).
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Strengths and Limitations
Although conducted post hoc, this analysis assessed
prespeciﬁed end points using prospectively collected data
sets, requiring no additional review or imputation. Electro-
cardiographic and echocardiographic data were adjudicated
in core laboratories. Analyses were investigator driven (N.V.)
and conducted independently without involvement of the
sponsor. However, our conclusions should be interpreted as
hypothesis generating, because the trial was prematurely
terminated, reducing the statistical power of any subgroup
analysis and tests for interactions. QRSd/LVEDV ratio was
not a stratiﬁcation factor at trial entry but LV dilatation was,
greatly reducing the number of patients with smaller
ventricles and the proportion of female enrollees (ie, our
interest groups). We indexed LVEDV to height. Indexing LV
volumes to body size has not been consistently followed in
CRT studies and may contribute to differing conclusions of
efﬁcacy among different studies.20 Structural remodeling
data are restricted to baseline to 6-months postimplantation
comparison in 621 patients (ie, 78% of the cohort) and not
aligned with outcome measures that were assessed at
19 months. Separating contributions to QRSd into either
increased path length (size) or conduction slowing by ratio is
an approximate method. HF remodeling is a complex
process affecting cardiomyocyte and interstitium. Impulse
propagation may be affected by LV dilatation but also at
tissue, cellular, and subcellullar levels. Thus ﬁbrosis, scar,
and reduced intercellular coupling will affect conduction
velocity as well as path length. We can only speculate on
mechanisms. LV epicardially paced wave fronts during CRT
generally propagate more slowly than normal intrinsic
conduction and are negatively inotropic, even in normal
myocardium.21 This action may be exaggerated in dilated
LVs without myocardial conduction delay, and risks harm.
On the contrary, when myocardial conduction is retarded,
the same stimulation in a smaller ventricle may restore
electrical synchrony and be clinically beneﬁcial.
Conclusion
In the EchoCRT trial, enrolled patients displayed large
heterogeneity in LV size, and the negative effects of CRT
were concentrated in men with larger ventricles. Conversely,
CRT appeared to be beneﬁcial in a minority with smallest
indexed LV volumes. These results add to the growing body of
data that QRSd assessment for CRT selection should include
attention to the nonelectrical modulating inﬂuences of LV
size, sex, and stature.3,4,6 The hypothesis that CRT may be
beneﬁcial in patients with HF with narrow QRSd and smaller
ventricles merits prospective evaluation.
Figure 3. Structural remodeling. Figures depict proportions of
patients in each group who demonstrated the combination of left
ventricular (LV) ejection fraction increase of ≥5% and LV end-systolic
volume decrease of ≥10% (ie, sustained a positive structural
remodeling9) in response to cardiac resynchronization therapy
(CRT) in patients grouped according to quartile (Q) ranges (QRS
duration [QRSd]/LV end-diastolic volume [LVEDV]Q1–Q3 vs QRSd/
LVEDVQ4). A, Overall. LV function improved in CRT-ON vs CRT-OFF
(42.3% [n=30] vs 24.1% [n=21]) (P=0.015) in the Q4 group. In
comparison, there was no change in QRSd/LVEDVQ1–Q3 (34.6%
[n=83] in CRT-ON vs 29.1% [n=65] in CRT-OFF; P=0.21; test for
interaction P=0.17). By sex. Echocardiographic data were available in
175women (CRT-ON vs CRT-OFF, 82 vs 93) and 446men (CRT-ON vs
CRT-OFF, 229 vs 217). CRT in men (B) produced no effect, but in
women (C), a beneﬁcial effect was seen in QRSd/LVEDVQ4Women (test
for interaction P=0.02).
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Table 7. Outcomes According to QRS/LVEDV, Separated by Sex
End Point Subgroup CRT-OFF
CRT-OFF, No.
(%) With Event CRT-ON
CRT-ON, No.
(%) With Event
Fully Adjusted Hazard
Ratio (95% Conﬁdence
Interval), P Value*
P Value for
Interaction
Between
Randomized
Treatment and Groupings
Men (n=565)
Death or HF hospitalization Q1–Q3 204 45 (22.06) 219 67 (30.59) 1.62 (1.09–2.41), 0.016 0.142
Q4 78 23 (29.49) 64 17 (26.56) 0.83 (0.40–1.74), 0.628
Death Q1–Q3 204 12 (5.88) 219 29 (13.24) 2.49 (1.21–5.15), 0.013 0.218
Q4 78 9 (11.54) 64 9 (14.06) 1.28 (0.41–3.94), 0.671
HF hospitalization Q1–Q3 204 40 (19.61) 219 56 (25.57) 1.52 (1.00– 2.32), 0.052 0.218
Q4 78 17 (21.79) 64 12 (18.75) 0.82 (0.35–1.93), 0.657
CVD death Q1–Q3 204 8 (3.92) 219 23 (10.50) 2.74 (1.16–6.49), 0.022 0.550
Q4 78 5 (6.41) 64 8 (12.50) 1.74 (0.40–7.49), 0.456
Women (n=222)
Death or HF hospitalization Q1–Q3 85 26 (30.59) 81 24 (29.63) 1.16 (0.62–2.19), 0.646 0.513
Q4 29 8 (27.59) 27 6 (22.22) 0.63 (0.16–2.54), 0.514
Death Q1–Q3 85 3 (3.53) 81 4 (4.94) 1.39 (0.23–8.47), 0.722 0.180
Q4 29 2 (6.90) 27 1 (3.70) 0.49 (0.03–8.22), 0.619
HF hospitalization Q1–Q3 85 26 (30.59) 81 23 (28.40) 1.12 (0.59–2.13), 0.729 0.749
Q4 29 7 (24.14) 27 6 (22.22) 0.79 (0.18–3.58), 0.763
CVD death Q1–Q3 85 3 (3.53) 81 4 (4.94) 1.39 (0.23–8.47), 0.722 . . .
Q4 29 1 (3.45) 27 0 (0.00)
Three-way test of interaction of sex with effects of QRS/LVEDV on CRT effect for outcomes: death/HF hospitalization, P=0.65; death, P=0.79; HF hospitalization, 0.52; and CVD death,
P=0.98. CRT indicates cardiac resynchronization therapy; Q1-3, QRSd/LVEDVQ1–Q3 ; Q4, QRSd/LVEDVQ4; CVD, cardiovascular disease; HF, heart failure; LVEDV, left ventricular end-
diastolic volume; and Q, quartile.
*Hazard ratio (95% conﬁdence interval) adjusted for country, walking distance, quality of life, sitting diastolic blood pressure, ischemic cardiomyopathy, history of myocardial infarction,
history of coronary artery bypass grafting, and diuretic use; P value from Wald test.
DOI: 10.1161/JAHA.118.009592 Journal of the American Heart Association 12
CRT in Patients With Heart Failure With Narrow QRS Varma et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on August 14, 2019
7. Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, Dickstein K,
Ford I, Gorcsan J III, Gras D, Krum H, Sogaard P, Holzmeister J. Cardiac-
resynchronization therapy in heart failure with a narrow QRS complex. N Engl J
Med. 2013;369:1395–1405.
8. Steffel J, Varma N, Robertson M, Singh JP, Bax JJ, Borer JS, Dickstein K, Ford I,
Gorcsan J III, Gras D, Krum H, Sogaard P, Holzmeister J, Brugada J, Abraham
WT, Ruschitzka F. Effect of gender on outcomes after cardiac resynchroniza-
tion therapy in patients with a narrow QRS complex: a subgroup analysis of the
EchoCRT trial. Circ Arrhythm Electrophysiol. 2016;9:pii: e003924.
9. Rickard J, Baranowski B, Wilson Tang WH, Grimm RA, Niebauer M, Cantillion D,
Wilkoff BL, Varma N. Echocardiographic predictors of long-term survival in
patients undergoing cardiac resynchronization therapy: what is the optimal
metric? J Cardiovasc Electrophysiol. 2017;28:410–415.
10. Dhingra R, Ho Nam B, Benjamin EJ, Wang TJ, Larson MG, D’Agostino RB Sr,
Levy D, Vasan RS. Cross-sectional relations of electrocardiographic QRS
duration to left ventricular dimensions: the Framingham Heart Study. J Am Coll
Cardiol. 2005;45:685–689.
11. Gettes LS, Kligﬁeld P. Should electrocardiogram criteria for the diagnosis of
left bundle-branch block be revised? J Electrocardiol. 2012;45:500–504.
12. Bacharova L, Szathmary V, Kovalcik M, Mateasik A. Effect of changes in left
ventricular anatomy and conduction velocity on the QRS voltage and
morphology in left ventricular hypertrophy: a model study. J Electrocardiol.
2010;43:200–208.
13. Stewart RA, Young AA, Anderson C, Teo KK, Jennings G, Cowan BR.
Relationship between QRS duration and left ventricular mass and volume in
patients at high cardiovascular risk. Heart. 2011;97:1766–1770.
14. Chan DD, Wu KC, Loring Z, Galeotti L, Gerstenblith G, Tomaselli G, Weiss RG,
Wagner GS, Strauss DG. Comparison of the relation between left ventricular
anatomy and QRS duration in patients with cardiomyopathy with versus
without left bundle branch block. Am J Cardiol. 2014;113:1717–1722.
15. Macfarlane P, Oosterom AV, Pahlm O. et al. Adult normal limits. in:
P. Macfarlane, A.V. Oosterom, O. Pahlm, P. Kligﬁeld, M. Janse, A.J. Camm
(Eds.) Comprehensive electrocardiology. 2011: 2057–2125.
16. Grant RP, Dodge HT. Mechanisms of QRS complex prolongation in man: left
ventricular conduction disturbances. Am J Med. 1956;20:834–852.
17. Strauss DG, Selvester RH, Wagner GS. Deﬁning left bundle branch block in the
era of cardiac resynchronization therapy. Am J Cardiol. 2011;107:927–934.
18. Steffel J, Robertson M, Singh JP, Abraham WT, Bax JJ, Borer JS, Dickstein K,
Ford I, Gorcsan J III, Gras D, Krum H, Sogaard P, Holzmeister J, Brugada J,
Ruschitzka F. The effect of QRS duration on cardiac resynchronization therapy
in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT
trial. Eur Heart J. 2015;36:1983–1989.
19. Jackson T, Claridge S, Behar J, Sammut E, Webb J, Carr-White G, Razavi R,
Rinaldi CA. Narrow QRS systolic heart failure: is there a target for cardiac
resynchronization? Expert Rev Cardiovasc Ther. 2015;13:783–797.
20. Fornwalt BK, Sprague WW, BeDell P, Suever JD, Gerritse B, Merlino JD, Fyfe DA,
Leon AR, Oshinski JN. Agreement is poor among current criteria used to deﬁne
response to cardiac resynchronization therapy. Circulation. 2010;121:1985–
1991.
21. Wiggers CJ. The muscular reactions of the mammalian ventricles to artiﬁcial
surface stimuli. Am J Physiol. 1925;73:346–378.
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
DOI: 10.1161/JAHA.118.009592 Journal of the American Heart Association 13
CRT in Patients With Heart Failure With Narrow QRS Varma et al
D
ow
nloaded from
 http://ahajournals.org by on August 14, 2019
